{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:46:09Z","timestamp":1790318769212,"version":"4.1.0"},"reference-count":100,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009845","name":"Ovarian Cancer Research Foundation (OCRF)","doi-asserted-by":"publisher","award":["GA-2019-20"],"award-info":[{"award-number":["GA-2019-20"]}],"id":[{"id":"10.13039\/100009845","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Victorian Government\u2019s Operational Infrastructure Support Program","award":["GA-2019-20"],"award-info":[{"award-number":["GA-2019-20"]}]},{"name":"Dr. Sue Fowler PhD Scholarship","award":["GA-2019-20"],"award-info":[{"award-number":["GA-2019-20"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Precision medicine has revolutionised targeted cancer treatments; however, its implementation in ovarian cancer remains challenging. Diverse tumour biology and extensive heterogeneity in ovarian cancer can limit the translatability of genetic profiling and contribute to a lack of biomarkers of treatment response. This review addresses the barriers in precision medicine for ovarian cancer, including obtaining adequate and representative tissue samples for analysis, developing functional and standardised screening methods, and navigating data infrastructure and management. Ethical concerns related to patient consent, data privacy and health equity are also explored. We highlight the socio-economic complexities for precision medicine and propose strategies to overcome these challenges with an emphasis on accessibility and education amongst patients and health professionals and the development of regulatory frameworks to support clinical integration. Interdisciplinary collaboration is essential to drive progress in precision medicine to improve disease management and ovarian cancer patient outcomes.<\/jats:p>","DOI":"10.3390\/curroncol31120592","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T09:43:03Z","timestamp":1734514983000},"page":"8023-8038","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Challenges in Implementing Comprehensive Precision Medicine Screening for Ovarian Cancer"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4496-2263","authenticated-orcid":false,"given":"Laura R.","family":"Moffitt","sequence":"first","affiliation":[{"name":"Hudson Institute of Medical Research, Clayton 3168, Australia"},{"name":"Department of Molecular and Translational Sciences, Monash University, Clayton 3168, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0702-2353","authenticated-orcid":false,"given":"Nazanin","family":"Karimnia","sequence":"additional","affiliation":[{"name":"Hudson Institute of Medical Research, Clayton 3168, Australia"},{"name":"Department of Molecular and Translational Sciences, Monash University, Clayton 3168, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2048-1027","authenticated-orcid":false,"given":"Amy L.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Hudson Institute of Medical Research, Clayton 3168, Australia"},{"name":"Department of Molecular and Translational Sciences, Monash University, Clayton 3168, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew N.","family":"Stephens","sequence":"additional","affiliation":[{"name":"Hudson Institute of Medical Research, Clayton 3168, Australia"},{"name":"Department of Molecular and Translational Sciences, Monash University, Clayton 3168, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1195-2296","authenticated-orcid":false,"given":"Gwo-Yaw","family":"Ho","sequence":"additional","affiliation":[{"name":"School of Clinical Sciences, Monash University, Clayton 3168, Australia"},{"name":"Department of Oncology, Monash Health, Bentleigh 3165, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6319-1153","authenticated-orcid":false,"given":"Maree","family":"Bilandzic","sequence":"additional","affiliation":[{"name":"Hudson Institute of Medical Research, Clayton 3168, Australia"},{"name":"Department of Molecular and Translational Sciences, Monash University, Clayton 3168, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Procter","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3322\/caac.21560","article-title":"The current state of molecular testing in the treatment of patients with solid tumors, 2019","volume":"69","author":"Goldberg","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.2696","article-title":"Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary","volume":"221","author":"Ahmed","year":"2010","journal-title":"J. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","article-title":"Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer","volume":"121","author":"Zhang","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_10","first-page":"14","article-title":"The promise and challenge of ovarian cancer models","volume":"4","author":"Hasan","year":"2015","journal-title":"Transl. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"8494","DOI":"10.1016\/j.biomaterials.2010.07.064","article-title":"Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells","volume":"31","author":"Loessner","year":"2010","journal-title":"Biomaterials"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/labinvest.2013.41","article-title":"A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro","volume":"93","author":"Lee","year":"2013","journal-title":"Lab. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1517\/17460441.2015.1091814","article-title":"High-throughput fluorescence imaging approaches for drug discovery using in vitro and in vivo three-dimensional models","volume":"10","author":"Martinez","year":"2015","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ymeth.2017.07.015","article-title":"Single cell-based automated quantification of therapy responses of invasive cancer spheroids in organotypic 3D culture","volume":"128","author":"Veelken","year":"2017","journal-title":"Methods"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Puls, T.J., Tan, X., Husain, M., Whittington, C.F., Fishel, M.L., and Voytik-Harbin, S.L. (2018). Development of a Novel 3D Tumor-tissue Invasion Model for High-throughput, High-content Phenotypic Drug Screening. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-31138-6"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/cge.13566","article-title":"Epithelial ovarian cancer risk: A review of the current genetic landscape","volume":"97","author":"Flaum","year":"2020","journal-title":"Clin. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jama.2017.21894","article-title":"Screening for Ovarian Cancer in Asymptomatic Women","volume":"319","author":"Lu","year":"2018","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Schwab, M. (2011). Ovarian Cancer Chemoresistance. Encyclopedia of Cancer, Springer.","DOI":"10.1007\/978-3-642-16483-5"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.18632\/oncotarget.14021","article-title":"Chemoresistance and targeted therapies in ovarian and endometrial cancers","volume":"8","author":"Brasseur","year":"2017","journal-title":"Oncotarget"},{"key":"ref_21","first-page":"288","article-title":"Recurrent epithelial ovarian cancer: An update on treatment","volume":"27","author":"Foley","year":"2013","journal-title":"Oncology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: Recommendations for improving outcomes","volume":"11","author":"Sebastian","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_23","unstructured":"Noone, A.M.H.N., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D.R., and Chen, H.S. (2018). SEER Cancer Statistics Review, 1975\u20132015, Based on November 2017 SEER Data Submission, Posted to the SEER Web Site, April 2018, National Cancer Institute."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","article-title":"Global epidemiology of epithelial ovarian cancer","volume":"21","author":"Webb","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11912-020-00933-8","article-title":"First-Line Management of Advanced High-Grade Serous Ovarian Cancer","volume":"22","author":"Mahmood","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/pgp.0b013e31803025cd","article-title":"Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis","volume":"26","author":"Wong","year":"2007","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ygyno.2012.10.013","article-title":"Quantification of ER\/PR expression in ovarian low-grade serous carcinoma","volume":"128","author":"Escobar","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal Maintenance Therapy for Women with Low-Grade Serous Cancer of the Ovary or Peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in Patients with Microsatellite Instability\u2013High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study","volume":"40","author":"Bariani","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Maoz, A., Matsuo, K., Ciccone, M.A., Matsuzaki, S., Klar, M., Roman, L.D., Sood, A.K., and Gershenson, D.M. (2020). Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord-Stromal Tumors: A Contemporary Review. Cancers, 12.","DOI":"10.3390\/cancers12061398"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/gyno.1998.5287","article-title":"Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary","volume":"73","author":"Wolf","year":"1999","journal-title":"Gynecol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Havasi, A., Cainap, S.S., Havasi, A.T., and Cainap, C. (2023). Ovarian Cancer-Insights into Platinum Resistance and Overcoming It. Medicina, 59.","DOI":"10.3390\/medicina59030544"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Wagner","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine Plus Carboplatin Compared with Carboplatin in Patients with Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial","volume":"32","author":"Hilpert","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/S0002-9378(94)70338-8","article-title":"Paclitaxel (Taxol) treatment for refractory ovarian cancer: Phase II clinical trial","volume":"170","author":"Seewaldt","year":"1994","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., Silva, I., Magalh\u00e3es, P., Schmidt, S., and Vale, N. (2024). Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16030332"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Subhan, M.A., Parveen, F., Shah, H., Yalamarty, S.S.K., Ataide, J.A., and Torchilin, V.P. (2023). Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type. Cancers, 15.","DOI":"10.3390\/cancers15082204"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.21037\/atm-20-1582","article-title":"Ovarian cancer risk assessment in the era of next-generation sequencing","volume":"8","author":"Bonadio","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"152595","DOI":"10.1016\/j.prp.2019.152595","article-title":"BRCA1\/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients","volume":"215","author":"Lee","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"v485","DOI":"10.1093\/annonc\/mdz253.016","article-title":"Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)","volume":"30","author":"Drew","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1038\/onc.2008.207","article-title":"HER2 regulates the mammary stem\/progenitor cell population driving tumorigenesis and invasion","volume":"27","author":"Korkaya","year":"2008","journal-title":"Oncogene"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000055405","article-title":"The predictive value of HER2 in breast cancer","volume":"61","author":"Piccart","year":"2001","journal-title":"Oncology"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Michelotti, A., de Scordilli, M., Bertoli, E., De Carlo, E., Del Conte, A., and Bearz, A. (2022). NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23126748"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/JTO.0000000000000074","article-title":"Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC","volume":"9","author":"Champiat","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1208\/s12248-020-00514-4","article-title":"Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors","volume":"22","author":"Gjoerup","year":"2020","journal-title":"AAPS J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and Safety of Avelumab for Patients with Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","article-title":"PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: A phase 1 trial","volume":"30","author":"Dorff","year":"2024","journal-title":"Nat. Med."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Ruiz-Garcia, E., and Astudillo-de la Vega, H. (2019). CAR-T cell and Personalized Medicine. Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics, Springer International Publishing.","DOI":"10.1007\/978-3-030-24100-1"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13287-022-02719-0","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress","volume":"13","author":"Budi","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2016.01.003","article-title":"Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don\u2019t know","volume":"141","author":"Liu","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41416-020-0763-4","article-title":"Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases","volume":"122","author":"Masoodi","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41698-018-0063-0","article-title":"Tumor evolution and chemoresistance in ovarian cancer","volume":"2","author":"Kim","year":"2018","journal-title":"Npj Precis. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1101\/gr.161026.113","article-title":"Genomic and transcriptomic plasticity in treatment-naive ovarian cancer","volume":"24","author":"Hoogstraat","year":"2014","journal-title":"Genome Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/path.4230","article-title":"Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling","volume":"231","author":"Bashashati","year":"2013","journal-title":"J. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","article-title":"Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: A Proof-of-Concept Phase II Study","volume":"26","author":"Lampert","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Guffanti, F., Mengoli, I., and Damia, G. (2024). Current HRD assays in ovarian cancer: Differences, pitfalls, limitations, and novel approaches. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1405361"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e2200695","DOI":"10.1200\/PO.22.00695","article-title":"Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary Breast and Ovarian Cancer","volume":"7","author":"Desai","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"102757","DOI":"10.1016\/j.isci.2021.102757","article-title":"Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens","volume":"24","author":"Hunt","year":"2021","journal-title":"iScience"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Craciun, L., Spinette, S.A., Rassy, M., Salgado, R., de Wind, A., Demetter, P., Verset, L., Gomez-Galdon, M., Chintinne, M., and Sirtaine, N. (2019). Tumor Banks: A Quality Control Scheme Proposal. Front. Med., 6.","DOI":"10.3389\/fmed.2019.00225"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jcmgh.2022.08.008","article-title":"Culture-Associated DNA Methylation Changes Impact on Cellular Function of Human Intestinal Organoids","volume":"14","author":"Edgar","year":"2022","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_70","unstructured":"Hedges, L.V., and Olkin, I. (2014). Statistical Methods for Meta-Analysis, Academic Press."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Mikolajewicz, N., and Komarova, S.V. (2019). Meta-Analytic Methodology for Basic Research: A Practical Guide. Front. Physiol., 10.","DOI":"10.3389\/fphys.2019.00203"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e24531","DOI":"10.1002\/jcla.24531","article-title":"Preanalytical DNA assessment for downstream applications: How to optimize the management of human biospecimens to support molecular diagnosis\u2014An experimental study","volume":"36","author":"Mordenti","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"100282","DOI":"10.1016\/j.labinv.2023.100282","article-title":"A High-Throughput PIXUL-Matrix-Based Toolbox to Profile Frozen and Formalin-Fixed Paraffin-Embedded Tissues Multiomes","volume":"104","author":"Mar","year":"2024","journal-title":"Lab. Investig."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2020.10.027","article-title":"Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer","volume":"160","author":"Matsuo","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/clinchem\/hvad194","article-title":"Critical Factors in the Analytical Work Flow of Circulating Tumor DNA-Based Molecular Profiling","volume":"70","author":"Schuuring","year":"2024","journal-title":"Clin. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.4389","article-title":"Functional precision cancer medicine\u2014Moving beyond pure genomics","volume":"23","author":"Letai","year":"2017","journal-title":"Nat. Med."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Napoli, G.C., Figg, W.D., and Chau, C.H. (2022). Functional Drug Screening in the Era of Precision Medicine. Front. Med., 9.","DOI":"10.3389\/fmed.2022.912641"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"Fso190","DOI":"10.4155\/fsoa-2017-0003","article-title":"Ex vivo tumor culture systems for functional drug testing and therapy response prediction","volume":"3","author":"Meijer","year":"2017","journal-title":"Future Sci. OA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"11473","DOI":"10.1073\/pnas.0604348103","article-title":"Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical libraries","volume":"103","author":"Inglese","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/1087057107312628","article-title":"Quantitative assessment of hit detection and confirmation in single and duplicate high-throughput screenings","volume":"13","author":"Wu","year":"2008","journal-title":"J. Biomol. Screen."},{"key":"ref_81","unstructured":"Wetterstrand, K.A. (2013). DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP), National Human Genome Research Institute."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Honeyford, K., Expert, P., Mendelsohn, E.E., Post, B., Faisal, A.A., Glampson, B., Mayer, E.K., and Costelloe, C.E. (2022). Challenges and recommendations for high quality research using electronic health records. Front. Digit. Health, 4.","DOI":"10.3389\/fdgth.2022.940330"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1002\/ctd2.217","article-title":"Strategy on precision medicine multidisciplinary team in clinical practice","volume":"3","author":"Qian","year":"2023","journal-title":"Clin. Transl. Discov."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Stefanicka-Wojtas, D., and Kurpas, D. (2023). Barriers and Facilitators to the Implementation of Personalised Medicine across Europe. J. Pers. Med., 13.","DOI":"10.3390\/jpm13020203"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1038\/s41436-021-01267-x","article-title":"Challenges in genetic testing: Clinician variant interpretation processes and the impact on clinical care","volume":"23","author":"Berrios","year":"2021","journal-title":"Genet. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41431-023-01373-1","article-title":"Community concerns about genetic discrimination in life insurance persist in Australia: A survey of consumers offered genetic testing","volume":"32","author":"Tiller","year":"2024","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41231-019-0050-7","article-title":"Lost in translation: The valley of death across preclinical and clinical divide\u2014Identification of problems and overcoming obstacles","volume":"4","author":"Seyhan","year":"2019","journal-title":"Transl. Med. Commun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41698-024-00711-w","article-title":"The economic costs of precision medicine for clinical translational research among children with high-risk cancer","volume":"8","author":"Owens","year":"2024","journal-title":"Npj Precis. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Eskander, R.N., Moore, K.N., Monk, B.J., Herzog, T.J., Annunziata, C.M., O\u2019Malley, D.M., and Coleman, R.L. (2023). Overcoming the challenges of drug development in platinum-resistant ovarian cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1258228"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ajmg.a.35811","article-title":"Barriers for integrating personalized medicine into clinical practice: A qualitative analysis","volume":"161","author":"Najafzadeh","year":"2013","journal-title":"Am. J. Med. Genet. Part A"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jamia\/ocw004","article-title":"A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients","volume":"23","author":"Cheng","year":"2016","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10147-023-02439-2","article-title":"Platform trial for off-label oncology drugs using comprehensive genomic profiling under the universal public healthcare system: The BELIEVE trial","volume":"29","author":"Ishimaru","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Jamrat, S., Sukasem, C., Sratthaphut, L., Hongkaew, Y., and Samanchuen, T. (2023). A precision medicine approach to personalized prescribing using genetic and nongenetic factors for clinical decision-making. Comput. Biol. Med., 165.","DOI":"10.1016\/j.compbiomed.2023.107329"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-024-01760-0","article-title":"New clinical trial design in precision medicine: Discovery, development and direction","volume":"9","author":"Duan","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00038-019-01298-x","article-title":"Cost-effectiveness of precision medicine: A scoping review","volume":"64","author":"Kasztura","year":"2019","journal-title":"Int. J. Public Health"},{"key":"ref_96","unstructured":"The Royal Australian College of General Practitioners (2016). Consultations conducted in languages other than English in Australian general practice. Aust. J. Gen. Pract., 45, 9\u201313."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5694\/mja2.52346","article-title":"Towards precision cancer medicine for Aboriginal and Torres Strait Islander cancer health equity","volume":"221","author":"Barngarla","year":"2024","journal-title":"Med. J. Aust."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","article-title":"Clinical use of current polygenic risk scores may exacerbate health disparities","volume":"51","author":"Martin","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1200\/OP.21.00236","article-title":"Black Is Diverse: The Untapped Beauty and Benefit of Cancer Genomics and Precision Medicine","volume":"17","author":"George","year":"2021","journal-title":"JCO Oncol. Pract."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Bishop, M.R., Omeler-Fenaud, S.M., Huskey, A.L.W., and Merner, N.D. (2020). Gene panel screening for insight towards breast cancer susceptibility in different ethnicities. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0238295"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/12\/592\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:54:33Z","timestamp":1760115273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/12\/592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":100,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["curroncol31120592"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31120592","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]}}}